Search - tctmd.com

Displaying 41 - 60 of 123

Sort: Relevancy | Date

In COVID-19 Patients, Vaccination Linked to Lower MACE Risk

News Daily News

In COVID-19 Patients, Vaccination Linked to Lower MACE Risk

Michael O'Riordan

February 22, 2023

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

January 24, 2023

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

News Daily News

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Michael O'Riordan

January 20, 2023

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

News Daily News

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

January 19, 2023

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

December 2022 News Roundup

News Opinion CV Team Dispatch

December 2022 News Roundup

December 28, 2022

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

Myocarditis After COVID-19 Vaccination Less Serious Than Prepandemic Cases

News Daily News

Myocarditis After COVID-19 Vaccination Less Serious Than Prepandemic Cases

December 06, 2022

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

News Conference News AHA 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Michael O'Riordan

November 10, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

High-Sensitivity Troponin Testing on the Rise in the US, but Still Limited

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

New Biomarker-Based Risk Score Performs Well in ACS

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.